Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stock Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

ABUS

Arbutus Biopharma (NASDAQ:ABUS) Stock Sees Selling Pressure At Higher Level

Arbutus Biopharma (NASDAQ:ABUS) dropped 9% last week. The company and Vaccitech Plc (NASDAQ: VACC) collaborated to study a combination of chronic hepatitis B virus treatment for patients receiving standard-of-care nucleotide reverse transcriptase inhibitor therapy. The companies will assess the pharmacokinetics, immunogenicity, antiviral activity, and safety of the company’s AB-729 combination, followed by Vaccitech’s VTP-300 in …

Continue reading “Arbutus Biopharma (NASDAQ:ABUS) Stock Sees Selling Pressure At Higher Level”

Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
*By submitting your information you agree to the terms of our Privacy Policy. You will receive the DRP Journal newsletter, and third party offers. You can unsubscribe anytime by selecting unsubscribe at the bottom of our emails.